{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:15:22Z","timestamp":1790270122105,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118472","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:27:35Z","timestamp":1789169255000},"page":"118472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["BMAL1 mediates venetoclax resistance in acute myeloid leukemia by interacting with TPD52"],"prefix":"10.1016","volume":"254","author":[{"given":"Songyang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxiao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifei","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118472_b0005","doi-asserted-by":"crossref","unstructured":"N.A., Acute myeloid leukemia stem cells: origin, characteristics, and clinical implications, Stem Cell. Rev. Rep.18 (2022) 1211-1226, doi:10.1007\/s12015-021-10308-6.","DOI":"10.1007\/s12015-021-10308-6"},{"key":"10.1016\/j.bcp.2026.118472_b0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14204995","article-title":"Targeting apoptosis in AML: where do we stand?","volume":"14","author":"Krawiec","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118472_b0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118472_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101288","article-title":"Navigating acute myeloid leukemia towards better outcomes:treatment pathways and challenges for patients ineligible for intensive chemotherapy","author":"Palmieri","year":"2025","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcp.2026.118472_b0025","doi-asserted-by":"crossref","unstructured":"C.D., Azacitidine and venetoclax in previously untreated acute myeloid leukemia, N. Engl. J. Med. 383 (2020) 617-629, doi:10.1056\/NEJMoa2012971.","DOI":"10.1056\/NEJMoa2012971"},{"key":"10.1016\/j.bcp.2026.118472_b0030","doi-asserted-by":"crossref","unstructured":"C.D., Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia:a non-randomised, open-label, phase 1b study, Lancet Oncol 19 (2018) 216-228, doi:10.1016\/s1470-2045(18)30010-x.","DOI":"10.1016\/S1470-2045(18)30010-X"},{"key":"10.1016\/j.bcp.2026.118472_b0035","doi-asserted-by":"crossref","unstructured":"D.A., Venetoclax for AML: changing the treatment paradigm, Blood Adv. 3 (2019) 4326-4335, doi:10.1182\/bloodadvances.2019000937.","DOI":"10.1182\/bloodadvances.2019000937"},{"key":"10.1016\/j.bcp.2026.118472_b0040","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3324\/haematol.2024.286589","article-title":"Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia","volume":"110","author":"Jim\u00e9nez-Vicente","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2026.118472_b0045","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/HS9.0000000000000572","article-title":"Treatment for relapsed\/refractory acute myeloid leukemia","volume":"5","author":"Thol","year":"2021","journal-title":"Hemasphere"},{"key":"10.1016\/j.bcp.2026.118472_b0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bcp.2026.118472_b0055","doi-asserted-by":"crossref","unstructured":"C.D., Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML, Blood 135 (2020) 791-803, doi:10.1182\/blood.2019003988.","DOI":"10.1182\/blood.2019003988"},{"key":"10.1016\/j.bcp.2026.118472_b0060","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2026.118472_b0065","doi-asserted-by":"crossref","unstructured":"H.A., Venetoclax-resistant MV4-11 leukemic cells activate PI3K\/AKT pathway for metabolic reprogramming and redox adaptation for survival, Antioxidants (Basel) 2022; 11, doi:10.3390\/antiox11030461.","DOI":"10.3390\/antiox11030461"},{"key":"10.1016\/j.bcp.2026.118472_b0070","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood.2020006343","article-title":"CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues","volume":"138","author":"Yu","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118472_b0075","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214829120","article-title":"Circadian regulator BMAL1::CLOCK promotes cell proliferation in hepatocellular carcinoma by controlling apoptosis and cell cycle","volume":"120","author":"Qu","year":"2023","journal-title":"PNAS"},{"key":"10.1016\/j.bcp.2026.118472_b0080","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1074\/jbc.M115.713412","article-title":"Circadian clock in a mouse colon tumor regulates intracellular iron levels to promote tumor progression","volume":"291","author":"Okazaki","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118472_b0085","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/s41388-023-02603-y","article-title":"BMAL1 collaborates with CLOCK to directly promote DNA double-strand break repair and tumor chemoresistance","volume":"42","author":"Zhang","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.bcp.2026.118472_b0090","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.gendis.2022.05.014","article-title":"The role of circadian clocks in cancer:mechanisms and clinical implications","volume":"10","author":"Liu","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.bcp.2026.118472_b0095","doi-asserted-by":"crossref","unstructured":"R.V., Core circadian clock genes regulate leukemia stem cells in AML, Cell 165 (2016) 303-316, doi:10.1016\/j.cell.2016.03.015.","DOI":"10.1016\/j.cell.2016.03.015"},{"key":"10.1016\/j.bcp.2026.118472_b0100","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1111\/cas.15875","article-title":"Circadian clock protein Bmal1 accelerates acute myeloid leukemia by inhibiting ferroptosis through the EBF3\/ALOX15 axis","volume":"114","author":"Wang","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bcp.2026.118472_b0105","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00432-024-05753-y","article-title":"Targeting BMAL1 reverses drug resistance of acute myeloid leukemia cells and promotes ferroptosis through HMGB1-GPX4 signaling pathway","volume":"150","author":"Zheng","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118472_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112054","article-title":"BMAL1-depletion remodels ceramide metabolism to regulate ferroptosis and sorafenib chemosensitivity in acute myeloid leukemia","volume":"28","author":"Zheng","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.bcp.2026.118472_b0115","doi-asserted-by":"crossref","unstructured":"E.A., Acquired multidrug resistance in AML is caused by low apoptotic priming in relapsed myeloblasts, Blood Cancer Discov. 5 (2024) 180-201, doi:10.1158\/2643-3230.Bcd-24-0001.","DOI":"10.1158\/2643-3230.BCD-24-0001"},{"key":"10.1016\/j.bcp.2026.118472_b0120","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/bjh.19314","article-title":"Venetoclax resistance in acute myeloid leukaemia: clinical and biological insights","volume":"204","author":"Nachmias","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcp.2026.118472_b0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ebiom.2019.07.004","article-title":"Aryl hydrocarbon receptor nuclear translocator-like (ARNTL\/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A","volume":"45","author":"Burgermeister","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bcp.2026.118472_b0130","doi-asserted-by":"crossref","first-page":"16023","DOI":"10.1038\/s41598-018-34433-4","article-title":"Opposite carcinogenic effects of circadian clock gene BMAL1","volume":"8","author":"Korkmaz","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118472_b0135","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood-2004-07-2630","article-title":"Tumor protein D52 (TPD52):a novel B-cell\/plasma-cell molecule with unique expression pattern and Ca(2+)-dependent association with annexin VI","volume":"105","author":"Tiacci","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118472_b0140","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.bbrc.2018.12.039","article-title":"Lipid storage and lipophagy regulates ferroptosis","volume":"508","author":"Bai","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2026.118472_b0145","doi-asserted-by":"crossref","unstructured":"J.A., Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene? Tumour. Biol. 35 (2014) 7369-7382, doi: 10.1007\/s13277-014-2006-x.","DOI":"10.1007\/s13277-014-2006-x"},{"key":"10.1016\/j.bcp.2026.118472_b0150","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7150\/thno.20356","article-title":"PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1\/AMPK-mediated autophagy","volume":"8","author":"Zeng","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.bcp.2026.118472_b0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/cco-23-156","article-title":"TPD52 is a prognostic biomarker and potential therapeutic target for ER+\/PR+\/HER2+ breast cancer","volume":"13","author":"Cheng","year":"2024","journal-title":"Chin. Clin. Oncol."},{"key":"10.1016\/j.bcp.2026.118472_b0160","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1515\/med-2019-0049","article-title":"miR-107 enhances the sensitivity of breast cancer cells to paclitaxel","volume":"14","author":"Wang","year":"2019","journal-title":"Open Med. (Wars)"},{"key":"10.1016\/j.bcp.2026.118472_b0165","doi-asserted-by":"crossref","unstructured":"J.W., AML poor prognosis factor, TPD52, is associated with the maintenance of haematopoietic stem cells through regulation of cell proliferation, J. Cell Biochem. 122 (2021) 403-412, doi:10.1002\/jcb.29869.","DOI":"10.1002\/jcb.29869"},{"key":"10.1016\/j.bcp.2026.118472_b0170","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.1038\/s41598-019-46156-1","article-title":"Delayed recruiting of TPD52 to lipid droplets\u2013evidence for a \u201csecond wave\u201d of lipid droplet-associated proteins that respond to altered lipid storage induced by Brefeldin A treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118472_b0175","doi-asserted-by":"crossref","unstructured":"S.J., BMAL1\/p53 mediating bronchial epithelial cell autophagy contributes to PM2.5-aggravated asthma, Cell Commun. Signal 2023; 21: 39, doi:10.1186\/s12964-023-01057-9.","DOI":"10.1186\/s12964-023-01057-9"},{"key":"10.1016\/j.bcp.2026.118472_b0180","doi-asserted-by":"crossref","unstructured":"T.J., CLOCK and BMAL1 stabilize and activate RHOA to promote F-actin formation in cancer cells, Exp. Mol. Med. 50 (2018) 1-15, doi:10.1038\/s12276-018-0156-4.","DOI":"10.1038\/s12276-018-0156-4"},{"key":"10.1016\/j.bcp.2026.118472_b0185","doi-asserted-by":"crossref","unstructured":"R.M., BMAL1 and ARNT enable circadian HIF2\u03b1 responses in clear cell renal cell carcinoma, Nat. Commun. 16 (2025) 5834. doi:10.1038\/s41467-025-60904-0.","DOI":"10.1038\/s41467-025-60904-0"},{"key":"10.1016\/j.bcp.2026.118472_b0190","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/s41586-025-08898-z","article-title":"BMAL1-HIF2A heterodimer modulates circadian variations of myocardial injury","volume":"641","author":"Ruan","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118472_b0195","doi-asserted-by":"crossref","first-page":"25925","DOI":"10.1074\/jbc.M114.567628","article-title":"Liver clock protein BMAL1 promotes de novo lipogenesis through insulin-mTORC2-AKT signaling","volume":"289","author":"Zhang","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2026.118472_b0200","unstructured":"Z.Y.Z., Investigation of the transcriptional regulation of tumor protein D52 isoform 3, Beijing Normal University, 2018."},{"key":"10.1016\/j.bcp.2026.118472_b0205","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11123186","article-title":"An overview on lipid droplets accumulation as novel target for acute myeloid leukemia therapy","volume":"11","author":"Nistic\u00f2","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bcp.2026.118472_b0210","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bcp.2026.118472_b0215","doi-asserted-by":"crossref","unstructured":"J.M., Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML, Sci. Rep. 11 (2021) 5838, doi:10.1038\/s41598-021-84708-6.","DOI":"10.1038\/s41598-021-84708-6"},{"key":"10.1016\/j.bcp.2026.118472_b0220","first-page":"984","article-title":"Targeting of PI3K\/AKT signaling and DNA damage response in acute myeloid leukemia:a novel therapeutic strategy to boost chemotherapy response and overcome resistance","volume":"4","author":"Estruch","year":"2021","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.bcp.2026.118472_b0225","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41586-024-07410-3","article-title":"Targetable leukaemia dependency on noncanonical PI3K\u03b3 signalling","volume":"630","author":"Luo","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2026.118472_b0230","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood.2023022202","article-title":"PI3K\u03b3 maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway","volume":"143","author":"Gu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2026.118472_b0235","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s43018-024-00782-5","article-title":"Targeting a lineage-specific PI3K\u03b3-Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader molecule","volume":"5","author":"L.M.","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.bcp.2026.118472_b0240","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-17-3024","article-title":"Cotargeting BCL-2 and PI3K induces BAX-dependent mitochondrial apoptosis in AML cells","volume":"78","author":"Rahmani","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2026.118472_b0245","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2017.11.006","article-title":"Dueling for dual inhibition:means to enhance effectiveness of PI3K\/Akt\/mTOR inhibitors in AML","volume":"32","author":"Herschbein","year":"2018","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcp.2026.118472_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090332","article-title":"Clonal heterogeneity reflected by PI3K-AKT-mTOR signaling in human acute myeloid leukemia cells and its association with adverse prognosis","volume":"10","author":"Nepstad","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bcp.2026.118472_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113192","article-title":"Targeting PI3K\/AKT\/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax","volume":"417","author":"Liu","year":"2022","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bcp.2026.118472_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092934","article-title":"Targeting PI3K\/Akt\/mTOR in AML:rationale and clinical evidence","volume":"9","author":"Darici","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bcp.2026.118472_b0265","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-22-1221","article-title":"Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia","volume":"28","author":"Yin","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:51:50Z","timestamp":1790268710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":53,"alternative-id":["S0006295226008129"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118472","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BMAL1 mediates venetoclax resistance in acute myeloid leukemia by interacting with TPD52","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118472"}}